Search by Drug Name or NDC
NDC 00069-2362-10 Comirnaty 0.048 mg/.48mL Details
Comirnaty 0.048 mg/.48mL
Comirnaty is a INTRAMUSCULAR INJECTION, SUSPENSION in the VACCINE category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is RAXTOZINAMERAN.
MedlinePlus Drug Summary
Why get vaccinated? COVID-19, mRNA vaccine can prevent COVID-19 disease. COVID-19 disease is caused by a coronavirus called SARS-CoV-2. You can get COVID-19 through contact with another person who has the virus. It is predominantly a respiratory (lung) illness, but it can also affect other organs. People with COVID-19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness leading to death. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever, chills, cough, shortness of breath, fatigue, muscle or body aches, headache, loss of taste or smell, sore throat, congestion, runny nose, nausea, vomiting, or diarrhea.
Related Packages: 00069-2362-10Last Updated: 03/24/2024
MedLinePlus Full Drug Details: COVID-19 Vaccine, mRNA
Product Information
| NDC | 00069-2362 |
|---|---|
| Product ID | 0069-2362_a0e017dc-e076-48f3-9cb6-c2d3608b26f8 |
| Associated GPIs | |
| GCN Sequence Number | 085216 |
| GCN Sequence Number Description | COVID vac 23-24(12up)(raxt)/PF VIAL 30 MCG/0.3 INTRAMUSC |
| HIC3 | Z0L |
| HIC3 Description | COVID-19 VACCINES |
| GCN | 54638 |
| HICL Sequence Number | 049179 |
| HICL Sequence Number Description | COVID VAC 2023-24 (12 YR AND UP) XBB.1.5 (RAXTOZINAMERAN)/PF |
| Brand/Generic | Brand |
| Proprietary Name | Comirnaty |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | COVID-19 Vaccine, mRNA |
| Product Type | VACCINE |
| Dosage Form | INJECTION, SUSPENSION |
| Route | INTRAMUSCULAR |
| Active Ingredient Strength | 0.048 |
| Active Ingredient Units | mg/.48mL |
| Substance Name | RAXTOZINAMERAN |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Pharmaceutical Class | n/a |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA125742 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00069-2362-10 (00069236210)
| NDC Package Code | 0069-2362-10 |
|---|---|
| Billing NDC | 00069236210 |
| Package | 10 VIAL, SINGLE-DOSE in 1 CARTON (0069-2362-10) / .48 mL in 1 VIAL, SINGLE-DOSE (0069-2362-01) |
| Marketing Start Date | 2023-09-11 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |